| Literature DB >> 25874150 |
Süreyya Yilmaz1, Fusun Topcu1, Hadice Selimoglu Sen1, Yasar Yildirim2, Zülfükar Yilmaz2, Ali Veysel Kara2, Cihan Akgul Ozmen3.
Abstract
Antiphospholipid syndrome (APS) is an autoimmune disease characterised by arterial and/or venous thrombosis and/or recurrent pregnancy loss in the presence of antiphospholipid (APL) antibodies. It is evaluated as APS when it develops associated with other systemic autoimmune diseases or primary APS if there is no concomitant disorder. In this study, we present a case of a 16-year-old male patient with primary APS. The patient was admitted with presumptive diagnosis of pneumonia, but multiple pulmonary thromboembolism (PTE) was observed on computerized tomography (CT) pulmonary angiography. APL antibodies positivity and thrombocytopenia developed in our patient. The patient was evaluated as primary APS since another etiology that could explain PTE was not found. Primary APS is a rare disease in children along with adolescents, compared with APS associated with other systemic autoimmune diseases. We present here a young male patient with primary APS and PTE to contribute to the literature. The patient initially had pneumonia but later developed PTE and thrombocytopenia.Entities:
Year: 2015 PMID: 25874150 PMCID: PMC4385638 DOI: 10.1155/2015/249612
Source DB: PubMed Journal: Case Rep Pulmonol ISSN: 2090-6854
Figure 1Consolidation areas in the lower lobe of right lung, upper-lower lobe of left lung, and lingula were observed in first drawn contrast enhanced computed tomography.
Figure 2PTE was detected on the right main pulmonary artery and left pulmonary artery branches and consolidation areas in bilateral lower lobe and areas of ground glass in the upper and lower lobes in computed tomography pulmonary angiography.
Thrombophilia panel of patient.
| Parameters | Initially | 13th week | References |
|---|---|---|---|
| Lac Confirm | 66.2 sec | 58.1 sec | 30–38 |
| Lac Screen | 125 sec | 102 sec | 31–44 |
| Lac S/Lac C | 1.89 | 1.76 | 0.8–1.2 |
| AT 3 activity | 89% | — | 84.6–120 |
| F VIII | 36.8% | — | 50–150 |
| Anticardiolipin IgM | 22.6 U/mL | 17.2 U/mL | 0–7 |
| Anticardiolipin IgG | 72.6 U/mL | 60.3 U/mL | 0–10 |
| aPTT | 38 sec | 48.6 sec | 25–35 |
| INR | 1.1 | 2.1 | 0.88–1.2 |
| PAI-1 (4G/5G) | Heterozygous | — | |
| MTHFR (C677T) | Heterozygous | — | |
| MTHFR (A1298C) | Normal | — | |
| F XIII | Normal | — | |
| F II (G20210A) | Heterozygous | — | |
| F V Leiden | Normal | — | |
| Protein C | Normal | — | |
| Protein S | Normal | — | |
| Platelet count | 108 × 109/L | 255 × 109/L | 142–424 |
Lac: Lupus anticoagulant, MTHFR: methylenetetrahydrofolate reductase, F: factor, and PAI: plasminogen activator inhibitor.